Lineage Cell Therapeutics (LCTX) Debt Ratio (2014 - 2021)

Lineage Cell Therapeutics has reported Debt Ratio for 6 years, with the latest figure at 0.0 in Q1 2021.

• For the quarter ending Q1 2021, Debt Ratio changed N/A year-over-year to 0.0; the trailing twelve-month figure through Mar 2021 stood at 0.0 (changed N/A YoY), and the FY2020 full-year result was 0.0, changed N/A from the prior year.
• Debt Ratio for Q1 2021 stood at 0.0, down from 0.0 in the prior quarter.
• The five-year high for Debt Ratio was 0.01 in Q3 2020, with the low at 0.0 in Q4 2017.
• Historically, Debt Ratio has averaged 0.0 across 3 years, with a median of 0.0 in 2021.
• The largest YoY upside for Debt Ratio was 70.37% in 2017 against a maximum downside of 87.66% in 2017.
• Lineage Cell Therapeutics' Debt Ratio stood at 0.0 in 2017, then soared by 4562.96% to 0.0 in 2020, then decreased by 15.62% to 0.0 in 2021.
• The last three Debt Ratio figures came in at 0.0 (Q1 2021), 0.0 (Q4 2020), and 0.01 (Q3 2020), per Business Quant data.